Home / Deep Research / Takayasu Arteritis

Takayasu Arteritis

1. Disease Information

2026-05-01
Falcon MONDO:0017991 Model: Edison Scientific Literature 41 citations

1. Disease Information

1.1 What is the disease? (concise overview)

Takayasu arteritis is a chronic granulomatous inflammatory large-vessel vasculitis that predominantly involves the aorta and its primary branches, leading to vessel-wall thickening and remodeling with stenosis/occlusion and/or aneurysm formation; clinical consequences arise from organ ischemia and vascular complications. This definition is explicit in the 2023 Chinese guideline (published 2024). (tian2024chineseguidelinefor pages 1-2)

The 2023 International Heart Journal review similarly defines TAK as “a chronic large vessel vasculitis with predilection to affect the aorta and its branches,” highlighting vessel-wall thickening/fibrosis and ischemic complications. (as2023currentdiagnosisand pages 1-2)

1.2 Key identifiers (available from retrieved sources)

  • ICD-10: M31.4 (Takayasu’s arteritis), explicitly used for case ascertainment in a Korean population-based survival study. (jang2021survivalandcauses pages 1-2)
  • MeSH: D013625 (“Takayasu Arteritis”), explicitly listed in multiple ClinicalTrials.gov condition browse modules. (NCT07491913 chunk 2, NCT02101333 chunk 2, NCT04882072 chunk 4, NCT02101333 chunk 3)
  • MONDO / Orphanet / OMIM / ICD-11: Not explicitly present in the retrieved full texts or clinical trial record chunks available in this tool run; therefore, these identifiers cannot be asserted here without external ontology lookup. (NCT02101333 chunk 2, jang2021survivalandcauses pages 1-2)

1.3 Common synonyms and alternative names

Authoritative sources and trial records show the following synonyms/alternative names: * Aortic arch syndrome, non-specific aortoarteritis, pulseless disease (explicitly listed as alternative names in the Korean population-based study). (jang2021survivalandcauses pages 1-2) * Aorto-arteritis, reversed coarctation of aorta (keywords in the 2023 Int Heart J review). (as2023currentdiagnosisand pages 1-2) * Abbreviations: TA, TAK. (as2023currentdiagnosisand pages 1-2)

1.4 Data provenance note (individual vs aggregated)

2. Etiology

2.1 Disease causal factors (current understanding)

The precise etiology remains incompletely defined, but TAK is strongly supported as an immune-mediated disease with both cellular and humoral immune components, featuring granulomatous arterial-wall inflammation that evolves into vascular remodeling. (bhandari2023pathophysiologydiagnosisand pages 3-4, as2023currentdiagnosisand pages 1-2)

2.2 Risk factors

2.2.1 Demographic risk signals

TAK preferentially affects young women and is more common in Asian populations in multiple reviews/guidelines. (tian2024chineseguidelinefor pages 1-2, as2023currentdiagnosisand pages 1-2)

2.2.2 Infectious association: tuberculosis (TB)

A 2023 meta-analysis of observational studies (30 studies; n=5,548) quantified TB burden among TAK patients: * Any TB infection prevalence: 31.27% (95% CI 20.48–43.11%) * Latent TB infection: 50.01% (95% CI 31.25–68.77%) * Active TB: 14.40% (95% CI 9.03–20.68%) * Strong regional variation (e.g., Western Pacific 16.93% vs African region 63.58%). (li2023prevalenceoftuberculosis pages 1-2)

These data support the expert conclusion to consider “rigorous TB screening measures and preventive interventions specifically tailored for the TAK population.” (li2023prevalenceoftuberculosis pages 1-2)

2.2.3 Genetic susceptibility (not monogenic)

A 2023 review describes TAK genetic susceptibility loci (e.g., HLA-B*52 highlighted in reviews; additional loci including IL12B, IL6 noted), consistent with a complex susceptibility architecture rather than a single causal gene. (bhandari2023pathophysiologydiagnosisand pages 8-9, as2023currentdiagnosisand pages 1-2)

2.3 Protective factors

No protective genetic or environmental factors were explicitly identified in the retrieved evidence; therefore, no protection claims are made here. (bhandari2023pathophysiologydiagnosisand pages 3-4)

2.4 Gene–environment interactions

The retrieved evidence supports an epidemiologic and mechanistic plausibility for infection-triggering hypotheses (e.g., TB antigens as triggers) but does not provide explicit gene–environment interaction datasets; therefore, this remains an evidence gap in this tool run. (as2023currentdiagnosisand pages 1-2, li2023prevalenceoftuberculosis pages 1-2)

3. Phenotypes

3.1 Core clinical phenotypes (with frequencies where available)

Pediatric data provide concrete phenotype frequencies. In a 15-year ambispective cohort of 101 childhood-onset TAK: * Hypertension: 70.3% * Blood pressure discrepancy: 55.4% * Bruits: 51.5% * Pulse deficits: 37.6% * Common arterial involvement: renal artery 62.4%, subclavian artery 43.6%, abdominal aorta 42.6%, carotid artery 42.6%. (fan2019clinicalcourseand pages 1-2)

Adult phenotypes are more variably described across cohorts, but ischemia-related manifestations (claudication, pulse inequality/loss, bruits) are consistently emphasized in reviews and guidelines. (tian2024chineseguidelinefor pages 1-2, as2023currentdiagnosisand pages 1-2)

3.2 Phenotype characteristics

3.3 Quality-of-life impact

The TAKT long-term extension study evaluated patient-reported outcomes via the SF-36 and reported clinically improved physical and mental component summary scores maintained over 96 weeks of tocilizumab treatment. (nakaoka2020longtermefficacyand pages 1-2)

3.4 Suggested HPO terms (examples)

(Phenotype frequencies are best supported by pediatric cohort data above; adult frequencies were not quantified in the retrieved evidence.) (fan2019clinicalcourseand pages 1-2)

4. Genetic/Molecular Information

4.1 Causal genes

TAK is not supported as a single-gene (Mendelian) disorder in the retrieved evidence. Instead, susceptibility loci and immune pathway genes (e.g., IL12B, IL6, HLA-B52) are implicated in association studies and mechanistic frameworks. (bhandari2023pathophysiologydiagnosisand pages 8-9, as2023currentdiagnosisand pages 1-2)

4.2 Pathogenic variants / modifier genes / chromosomal abnormalities

No ClinVar/ACMG-style variant assertions, population allele frequencies (gnomAD), or chromosomal abnormalities were present in the retrieved sources. Therefore, this section is an evidence gap in the current tool-accessible corpus. (bhandari2023pathophysiologydiagnosisand pages 8-9)

4.3 Epigenetics

No TAK-specific methylation/histone evidence was present in retrieved sources. (misra2023arterialwallfibrosis pages 1-2)

5. Environmental Information

5.1 Infectious agents

Mycobacterium tuberculosis is the main infectious agent highlighted across recent review and meta-analysis literature as a potential trigger/association; the 2023 meta-analysis quantified TB prevalence in TAK (see Etiology). (li2023prevalenceoftuberculosis pages 1-2, as2023currentdiagnosisand pages 1-2)

5.2 Lifestyle/environmental factors

No specific toxins/lifestyle exposures were quantified as risk modifiers in the retrieved evidence; one review mentions non-pharmacologic measures (e.g., smoking cessation, exercise) as supportive care but not as primary prevention evidence. (bhandari2023pathophysiologydiagnosisand pages 7-8)

6. Mechanism / Pathophysiology

6.1 Current mechanistic model (immune-to-vascular damage causal chain)

A consistent causal chain from recent mechanistic reviews can be summarized as: 1) Initiation at vasa vasorum / medio-adventitial junction with immune activation → panarteritis and wall thickening. (bhandari2023pathophysiologydiagnosisand pages 3-4) 2) Innate sensing and antigen presentation: aberrant vascular dendritic cells with upregulated TLR signaling release cytokines including IL-12, IL-23, IL-1β, recruiting vasculitogenic T cells. (bhandari2023pathophysiologydiagnosisand pages 3-4) 3) Effector lymphocyte injury: cytotoxic CD8+ T cells release perforin/granzymes; Th1/Th17 subsets contribute via IFN-γ/IL-17/IL-6-related pathways. (bhandari2023pathophysiologydiagnosisand pages 3-4, misra2023arterialwallfibrosis pages 1-2) 4) Macrophage polarization and tissue remodeling: M1 macrophages (IL-6) dominate inflammatory stages; with resolution, M2 macrophages secrete TGF-β and GPNMB, activating adventitial fibroblasts and promoting extracellular matrix deposition and fibrosis. (bhandari2023pathophysiologydiagnosisand pages 3-4, misra2023arterialwallfibrosis pages 1-2) 5) Fibrosis and stenosis: IL-6 and IL-17 promote fibroblast activation; Notch-1–driven mTORC1 activation in Th1/Th17 cells is described, linking immune activation to persistent remodeling/fibrosis. (misra2023arterialwallfibrosis pages 1-2, bhandari2023pathophysiologydiagnosisand pages 3-4)

This chain provides a mechanistic rationale for targeting cytokines (IL-6; TNF), T-cell pathways, and JAK/STAT signaling and (in future) anti-fibrotic strategies. (misra2023arterialwallfibrosis pages 1-2, bhandari2023pathophysiologydiagnosisand pages 5-7)

6.2 Suggested GO biological process terms (examples)

6.3 Suggested Cell Ontology (CL) terms (examples)

6.4 Molecular profiling and advanced technologies

The retrieved evidence discusses molecular profiling and biomarkers as future directions but does not provide a specific single-cell/spatial multi-omics dataset in the accessible excerpts; thus, detailed omics signatures are not asserted here. (bhandari2023pathophysiologydiagnosisand pages 8-9, bhandari2023pathophysiologydiagnosisand pages 5-7)

7. Anatomical Structures Affected

7.1 Organ/system level

Primary: aorta and major branches (large vessel vasculitis). (tian2024chineseguidelinefor pages 1-2, as2023currentdiagnosisand pages 1-2)

Common branch vessels (pediatric cohort frequencies): renal artery, subclavian artery, carotid artery, abdominal aorta involvement. (fan2019clinicalcourseand pages 1-2)

7.2 Suggested UBERON terms (examples)

8. Temporal Development

8.1 Onset

TAK often begins insidiously with non-specific constitutional symptoms; one review reports a mean delay from symptom onset to diagnosis of ~1.3 years (SD ±0.6). (as2023currentdiagnosisand pages 1-2)

8.2 Progression/course

A staged concept (active/chronic/healing; or inflammatory to fibrotic progression) is described in reviews, aligning clinical phases with inflammatory activity and subsequent fibrosis. (bhandari2023pathophysiologydiagnosisand pages 3-4, bhandari2023pathophysiologydiagnosisand pages 5-7)

9. Inheritance and Population

9.1 Epidemiology (recent numeric estimates from retrieved sources)

9.2 Sex ratio

Female predominance is consistent: * French multicenter cohort: 86.8% women (276/318). (comarmond2017longtermoutcomesand pages 1-4) * Pediatric cohort: 76.2% female. (fan2019clinicalcourseand pages 1-2)

9.3 Inheritance pattern

The retrieved evidence supports complex susceptibility (e.g., HLA association) rather than Mendelian inheritance; no penetrance/segregation data were available. (as2023currentdiagnosisand pages 1-2)

10. Diagnostics

10.1 Clinical criteria / classification

The 2022 ACR/EULAR classification criteria incorporate imaging characteristics as an absolute requirement (key recent change). (as2023currentdiagnosisand pages 1-2)

Disease activity assessment approaches in the Chinese guideline include Kerr criteria and ITAS2010/ITAS-A thresholds (e.g., ITAS2010 ≥2; ITAS-A ≥5 for active disease). (tian2024chineseguidelinefor pages 6-7)

10.2 Laboratory biomarkers

ESR and CRP are widely used but have limited accuracy for disease activity; pentraxin-3 (PTX3) is described as “relatively superior” and correlating with ITAS2010 in several studies (per review). (as2023currentdiagnosisand pages 1-2)

Other candidate biomarkers mentioned as promising but requiring validation include anti-endothelial cell antibodies, VEGF, IL-6, IL-8, and PTX3. (bhandari2023pathophysiologydiagnosisand pages 5-7)

10.3 Imaging

Current imaging principles in retrieved sources include: * CTA often recommended as an initial diagnostic imaging modality for availability and resolution (review). (bhandari2023pathophysiologydiagnosisand pages 5-7) * DSA remains a diagnostic gold standard/reference but is invasive and unsuitable for repeated follow-up. (bhandari2023pathophysiologydiagnosisand pages 5-7) * MRI/MRA preferred for surveillance in younger patients due to lack of radiation exposure. (bhandari2023pathophysiologydiagnosisand pages 5-7) * FDG-PET/CT can localize metabolically active arterial inflammation but has radiation limitations and variable interpretation of low-grade activity. (bhandari2023pathophysiologydiagnosisand pages 5-7) * A 2023 imaging SLR informing the EULAR update reported: “No new studies on diagnostic imaging for Takayasu arteritis (TAK) were found” for the 2017–2022 update window. (bosch2023imagingindiagnosis pages 1-2)

The Chinese guideline provides an algorithmic diagnostic/treatment pathway (Figure 1). (tian2024chineseguidelinefor media 1be88471)

10.4 Suggested LOINC-style lab signals (examples)

Not formally mapped in retrieved texts; typical monitoring includes ESR and CRP. (bhandari2023pathophysiologydiagnosisand pages 7-8, as2023currentdiagnosisand pages 1-2)

11. Outcome / Prognosis

11.1 Adult outcomes (multicenter cohort)

In a French nationwide multicenter study (n=318; median follow-up 6.1 years): * Relapses: 43% * Vascular complications: 38% * Death: 5% * 5- and 10-year event-free survival: 48.2% and 36.4% * 5- and 10-year relapse-free survival: 58.6% and 47.7% * 5- and 10-year complication-free survival: 69.9% and 53.7% (comarmond2017longtermoutcomesand pages 1-4)

Risk factors highlighted included progressive disease course and carotidodynia for worse EFS; male sex, elevated CRP, carotidodynia for relapse; thoracic aorta involvement and retinopathy for vascular complications. (comarmond2017longtermoutcomesand pages 1-4)

11.2 Pediatric outcomes

In childhood-onset TAK (n=101; median follow-up 2.4 years): events 44.6%, vascular complications 44.6%, flares 26.7%, death 3%; 5-year event-free survival 42.8%. (fan2019clinicalcourseand pages 1-2)

12. Treatment

12.1 Standard-of-care concepts

Across reviews and guidelines, glucocorticoids plus steroid-sparing immunosuppressants are emphasized, with biologics for refractory disease and revascularization procedures for critical lesions once inflammation is controlled. (bhandari2023pathophysiologydiagnosisand pages 7-8, tian2024chineseguidelinefor pages 1-2, bhandari2023pathophysiologydiagnosisand pages 5-7)

12.2 csDMARDs / immunosuppressants (examples)

Commonly referenced agents include methotrexate, azathioprine, mycophenolate mofetil, leflunomide, cyclophosphamide. (bhandari2023pathophysiologydiagnosisand pages 5-7, bhandari2023pathophysiologydiagnosisand pages 7-8)

12.3 Biologics and targeted therapy (key recent evidence)

Tocilizumab (IL-6R blockade)

A 2023 meta-analysis (19 studies, 466 refractory TAK patients) reported: * Remission rate: 79% (95% CI 69–86%) * Relapse rate: 17% (95% CI 5–45%) * Imaging progression: 16% (95% CI 9–27%) * Retention rate: 68% (95% CI 50–82%) * Adverse events: 16% (infection 12%) * ~76% achieved glucocorticoid dose reduction (kang2023systematicreviewand pages 1-2)

The TAKT randomized trial long-term extension (up to 96 weeks) showed steroid-sparing with median glucocorticoid dose decreasing from 0.223 mg/kg/day (pre-entry relapse) to 0.131 at 48 weeks and 0.105 at 96 weeks; 46.4% reduced to <0.1 mg/kg/day; imaging mostly stable/improved (improved 17.9%, stable 67.9%). (nakaoka2020longtermefficacyand pages 1-2)

TNF inhibitors

TNF inhibitors (e.g., infliximab, etanercept, adalimumab) are described as used for refractory TAK with partial clinical responses in many patients (uncontrolled/observational evidence). (bhandari2023pathophysiologydiagnosisand pages 5-7)

JAK inhibitors (emerging)

Recent guideline/review material notes JAK inhibitors as potentially effective and increasingly used/considered for refractory disease, but acknowledges limited controlled evidence and the need for careful safety consideration. (arita2024currentimmunosuppressivetreatment pages 5-5)

12.4 Interventional/surgical management

Revascularization (endovascular or open surgery) is used for critical symptomatic stenoses; guidance emphasizes delaying interventions until disease activity is controlled and performing procedures in specialized centers. (bhandari2023pathophysiologydiagnosisand pages 7-8)

12.5 Experimental/ongoing clinical trials (selected)

ClinicalTrials.gov records retrieved in this run include: * Tocilizumab in TAK: NCT02101333 (completed) (NCT02101333 chunk 2) * Baricitinib for refractory TAK: NCT06662721 (completed; phase 2) (clinical trial listing retrieved in tool run; see overall trial set) (NCT04300686 chunk 3) * Ustekinumab: NCT04882072 (terminated; phase 3) (NCT04882072 chunk 4) * Biologic withdrawal in sustained remission: NCT07491913 (recruiting) (NCT07491913 chunk 2)

12.6 Suggested MAXO terms (examples)

13. Prevention

13.1 Primary prevention

No established primary prevention strategy exists in the retrieved evidence.

13.2 Secondary/tertiary prevention

Given high TB prevalence in TAK populations and the immunosuppressive treatment context, TB screening and preventive strategies are strongly supported by the 2023 meta-analysis conclusion. (li2023prevalenceoftuberculosis pages 1-2)

Tertiary prevention includes aggressive control of inflammation to prevent stenosis/aneurysm complications and procedure timing during inactive disease. (bhandari2023pathophysiologydiagnosisand pages 7-8)

14. Other Species / Natural Disease

No naturally occurring TAK analog in non-human species was identified in the retrieved sources. This section is an evidence gap for this tool run. (misra2023arterialwallfibrosis pages 1-2)

15. Model Organisms

The retrieved sources reference experimental/“in vitro” mechanistic findings relevant to fibrosis modulation but do not provide a specific, well-validated animal model description in the accessible excerpts; therefore, model organism details are not asserted here. (misra2023arterialwallfibrosis pages 1-2)

Key recent (2023–2024) developments (high-level synthesis)

1) Classification/diagnostics shifting toward imaging: 2022 ACR/EULAR criteria require imaging; imaging-centric pathways are emphasized in guidelines and reviews. (as2023currentdiagnosisand pages 1-2, tian2024chineseguidelinefor media 1be88471) 2) Biologic and targeted therapies expanding: 2024 therapeutic review emphasizes growth of biologic DMARD use (notably tocilizumab) and anticipated increase in use; JAK inhibitors discussed as emerging options. (arita2024currentimmunosuppressivetreatment pages 5-5) 3) Fibrosis and damage as therapeutic targets: 2023 mechanistic review frames fibrosis as prominent in TAK and discusses potential anti-fibrotic modulation alongside immunosuppression. (misra2023arterialwallfibrosis pages 1-2) 4) Comorbidity screening implications: 2023 TB prevalence meta-analysis provides quantitative rationale for TB screening policies in TAK care pathways. (li2023prevalenceoftuberculosis pages 1-2)

Summary table (artifact)

The following table consolidates key quantitative facts and sources extracted in this run.

Table (click to expand)
Domain Key points (with numbers) Key sources (PMID/DOI/URL when available)
Core definition / overview Chronic granulomatous large-vessel vasculitis involving the aorta and major branches; causes wall thickening, stenosis/occlusion, aneurysm formation, and ischemic complications; often affects young women, especially in Asia (tian2024chineseguidelinefor pages 1-2, as2023currentdiagnosisand pages 1-2) Chinese guideline 2024, doi:10.1515/rir-2024-0002, https://doi.org/10.1515/rir-2024-0002 (tian2024chineseguidelinefor pages 1-2); Int Heart J 2023, doi:10.1536/ihj.23-195, https://doi.org/10.1536/ihj.23-195 (as2023currentdiagnosisand pages 1-2)
Epidemiology Annual incidence reported as ~1.11 per million person-years in one review; worldwide annual incidence ~2.6/million in Chinese guideline; global prevalence/frequency reported as 3.2–40.0 cases per million; Japan prevalence cited as ~60/million; women comprise 86.8% in a 318-patient multicenter cohort; childhood cohort 76.2% female (bhandari2023pathophysiologydiagnosisand pages 3-4, tian2024chineseguidelinefor pages 1-2, as2023currentdiagnosisand pages 1-2, nakaoka2020longtermefficacyand pages 1-2, fan2019clinicalcourseand pages 1-2, comarmond2017longtermoutcomesand pages 1-4) Rheumatology (Oxford) 2020, doi:10.1093/rheumatology/kez630, https://doi.org/10.1093/rheumatology/kez630 (nakaoka2020longtermefficacyand pages 1-2); Circulation 2017, doi:10.1161/CIRCULATIONAHA.116.027094, https://doi.org/10.1161/CIRCULATIONAHA.116.027094 (comarmond2017longtermoutcomesand pages 1-4)
Infectious / risk-factor signal Meta-analysis of 30 studies, n=5,548: pooled TB infection prevalence 31.27% (95% CI 20.48–43.11%); latent TB 50.01% (31.25–68.77%); active TB 14.40% (9.03–20.68%); African Region 63.58% vs Western Pacific 16.93%, supporting TB screening in TAK populations (li2023prevalenceoftuberculosis pages 1-2) Sci Rep 2023, doi:10.1038/s41598-023-49998-y, https://doi.org/10.1038/s41598-023-49998-y (li2023prevalenceoftuberculosis pages 1-2)
Pathophysiology Inflammation begins around vasa vasorum/medio-adventitial junction causing panarteritis; aberrant dendritic cells/TLR signaling release IL-12, IL-23, IL-1β; CD8+ T cells release perforin/granzymes; B-cell autoimmunity/anti-endothelial or anti-aorta antibodies implicated; M1 macrophages dominate active inflammation (IL-6, MMPs, ROS), M2 macrophages dominate fibrotic phase (TGF-β, PDGF, GPNMB) and activate fibroblasts; Th1/Th17, Th17.1, PD1+Th17, Notch-1/mTORC1, IL-6/IL-17/TGF-β pathways link inflammation to fibrosis (bhandari2023pathophysiologydiagnosisand pages 3-4, bhandari2023pathophysiologydiagnosisand pages 9-9, misra2023arterialwallfibrosis pages 1-2) Front Immunol 2023, doi:10.3389/fimmu.2023.1174249, https://doi.org/10.3389/fimmu.2023.1174249 (misra2023arterialwallfibrosis pages 1-2); Cureus 2023, doi:10.7759/cureus.42667, https://doi.org/10.7759/cureus.42667 (bhandari2023pathophysiologydiagnosisand pages 3-4)
Diagnostics: classification criteria 2022 ACR/EULAR classification criteria incorporate imaging as an absolute requirement; older criteria include Ishikawa 1988 and ACR 1990; Sharma modification improved sensitivity from 60% to 92.5% while preserving specificity; 2022 criteria reportedly sensitivity 90.5% and specificity 98.3% in DCVAS-related comparison vs ACR 1990 sensitivity 73.6% and specificity 97.8% (as2023currentdiagnosisand pages 1-2, bhandari2023pathophysiologydiagnosisand pages 9-10) Int Heart J 2023, doi:10.1536/ihj.23-195, https://doi.org/10.1536/ihj.23-195 (as2023currentdiagnosisand pages 1-2)
Diagnostics: activity scores / biomarkers Kerr criteria define active disease by ≥2 of 4 items; ITAS2010 active if score ≥2; ITAS-A active if ≥5; ESR/CRP have limited accuracy for activity; pentraxin-3 appears relatively superior in several studies; ESR remains commonly used and is included in activity frameworks; novel candidates include anti-endothelial cell antibodies, VEGF, IL-6, IL-8, PTX3 (bhandari2023pathophysiologydiagnosisand pages 5-7, tian2024chineseguidelinefor pages 6-7, as2023currentdiagnosisand pages 1-2) Chinese guideline 2024, doi:10.1515/rir-2024-0002, https://doi.org/10.1515/rir-2024-0002 (tian2024chineseguidelinefor pages 6-7); Int Heart J 2023, doi:10.1536/ihj.23-195, https://doi.org/10.1536/ihj.23-195 (as2023currentdiagnosisand pages 1-2)
Diagnostics: imaging CTA often favored as initial modality for availability/resolution; DSA remains reference gold standard but is invasive; MRI/MRA preferred for surveillance and younger patients due to no radiation; Doppler US/CEUS assess intima-media thickness and neovascularization; FDG-PET/CT can detect metabolically active arterial inflammation but has radiation burden and variable follow-up utility; 2023 EULAR imaging review found no new diagnostic imaging studies for TAK in 2017–2022 update (bhandari2023pathophysiologydiagnosisand pages 5-7, bhandari2023pathophysiologydiagnosisand pages 7-8, bosch2023imagingindiagnosis pages 1-2) RMD Open 2023, doi:10.1136/rmdopen-2023-003379, https://doi.org/10.1136/rmdopen-2023-003379 (bosch2023imagingindiagnosis pages 1-2); Cureus 2023, doi:10.7759/cureus.42667, https://doi.org/10.7759/cureus.42667 (bhandari2023pathophysiologydiagnosisand pages 5-7)
Treatments: standard and steroid-sparing Current practice uses glucocorticoids plus upfront steroid-sparing immunosuppressants rather than steroid monotherapy; csDMARDs include methotrexate, azathioprine, mycophenolate mofetil, leflunomide, cyclophosphamide; biologics for refractory disease include tocilizumab and TNF inhibitors; JAK inhibitors have emerging supportive reports (bhandari2023pathophysiologydiagnosisand pages 5-7, bhandari2023pathophysiologydiagnosisand pages 7-8, as2023currentdiagnosisand pages 1-2, arita2024currentimmunosuppressivetreatment pages 5-5) Circulation Journal 2024, doi:10.1253/circj.cj-23-0780, https://doi.org/10.1253/circj.cj-23-0780 (arita2024currentimmunosuppressivetreatment pages 5-5); Int Heart J 2023, doi:10.1536/ihj.23-195, https://doi.org/10.1536/ihj.23-195 (as2023currentdiagnosisand pages 1-2)
Treatments: tocilizumab outcomes Meta-analysis of 19 studies, n=466 refractory TAK: remission 79% (95% CI 69–86%), relapse 17% (5–45%), imaging progression 16% (9–27%), retention 68% (50–82%), adverse events 16% (5–39%), infection 12% (5–28%), ~76% achieved glucocorticoid reduction; long-term TAKT extension: median glucocorticoid dose fell from 0.223 mg/kg/day pre-entry relapse to 0.131 at 48 weeks and 0.105 at 96 weeks; 46.4% reduced to <0.1 mg/kg/day; imaging improved in 17.9% and stable in 67.9% after 96 weeks (kang2023systematicreviewand pages 1-2, nakaoka2020longtermefficacyand pages 1-2) Front Immunol 2023, doi:10.3389/fimmu.2023.1084558, https://doi.org/10.3389/fimmu.2023.1084558 (kang2023systematicreviewand pages 1-2); Rheumatology 2020, doi:10.1093/rheumatology/kez630, https://doi.org/10.1093/rheumatology/kez630 (nakaoka2020longtermefficacyand pages 1-2)
Outcomes / prognosis Multicenter 318-patient cohort: after median 6.1 years, relapses 43%, vascular complications 38%, death 5%; 5-/10-year event-free survival 48.2%/36.4%, relapse-free survival 58.6%/47.7%, complication-free survival 69.9%/53.7%; childhood cohort (n=101): events 44.6%, rehospitalization 37.6%, vascular complications 44.6%, flares 26.7%, death 3% at median 2.4 years; 5-year event-free survival 42.8% (fan2019clinicalcourseand pages 1-2, comarmond2017longtermoutcomesand pages 1-4) Circulation 2017, doi:10.1161/CIRCULATIONAHA.116.027094, https://doi.org/10.1161/CIRCULATIONAHA.116.027094 (comarmond2017longtermoutcomesand pages 1-4); Arthritis Res Ther 2019, doi:10.1186/s13075-018-1790-x, https://doi.org/10.1186/s13075-018-1790-x (fan2019clinicalcourseand pages 1-2)

Table: This table condenses the main evidence already retrieved in the chat on Takayasu arteritis, including definition, epidemiology, mechanisms, diagnosis, treatment, and prognosis. It is useful as a quick-reference artifact for building the full disease knowledge base entry with cited quantitative findings.

Visual evidence (guideline pathway)

The Chinese guideline includes a diagnosis-and-treatment algorithm figure.

(tian2024chineseguidelinefor media 1be88471)

Limitations of this report (due to tool-accessible corpus)

  • MONDO / Orphanet / OMIM / ICD-11 identifiers were not explicitly present in the retrieved texts and trial record chunks; they are therefore not asserted.
  • Variant-level genetics (ClinVar/ACMG), epigenetics, and detailed omics signatures were not available in retrieved excerpts.
  • Some requested items (e.g., model organisms, other species) were not covered by accessible sources in this run.

References

  1. (tian2024chineseguidelinefor pages 1-2): Xinping Tian and Xiaofeng Zeng. Chinese guideline for the diagnosis and treatment of takayasu’s arteritis (2023). Rheumatology and Immunology Research, 5:5-26, Mar 2024. URL: https://doi.org/10.1515/rir-2024-0002, doi:10.1515/rir-2024-0002. This article has 14 citations.

  2. (as2023currentdiagnosisand pages 1-2): Chandhu AS and Debashish Danda. Current diagnosis and management of takayasu arteritis. International heart journal, 64 4:519-534, Jul 2023. URL: https://doi.org/10.1536/ihj.23-195, doi:10.1536/ihj.23-195. This article has 14 citations and is from a peer-reviewed journal.

  3. (jang2021survivalandcauses pages 1-2): Shin Yi Jang, Taek Kyu Park, and Duk‐Kyung Kim. Survival and causes of death for takayasu’s arteritis in korea: a retrospective population‐based study. International Journal of Rheumatic Diseases, 24:69-73, Oct 2021. URL: https://doi.org/10.1111/1756-185x.14005, doi:10.1111/1756-185x.14005. This article has 24 citations and is from a peer-reviewed journal.

  4. (NCT07491913 chunk 2): Fatma Alibaz Oner. Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission. Marmara University. 2025. ClinicalTrials.gov Identifier: NCT07491913

  5. (NCT02101333 chunk 2): Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis. Assistance Publique - Hôpitaux de Paris. 2014. ClinicalTrials.gov Identifier: NCT02101333

  6. (NCT04882072 chunk 4): A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK). Janssen Pharmaceutical K.K.. 2021. ClinicalTrials.gov Identifier: NCT04882072

  7. (NCT02101333 chunk 3): Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis. Assistance Publique - Hôpitaux de Paris. 2014. ClinicalTrials.gov Identifier: NCT02101333

  8. (li2023prevalenceoftuberculosis pages 1-2): Liping Li, Fang Zhou, Fen Li, Jinwei Chen, and Xi Xie. Prevalence of tuberculosis infection among patients with takayasu arteritis: a meta-analysis of observational studies. Scientific Reports, Dec 2023. URL: https://doi.org/10.1038/s41598-023-49998-y, doi:10.1038/s41598-023-49998-y. This article has 10 citations and is from a peer-reviewed journal.

  9. (kang2023systematicreviewand pages 1-2): Limei Kang, Yang Liu, Zhongling Luo, Yueyuan Zhou, Bo Chen, Geng Yin, and Qibing Xie. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory takayasu arteritis. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1084558, doi:10.3389/fimmu.2023.1084558. This article has 15 citations and is from a peer-reviewed journal.

  10. (bosch2023imagingindiagnosis pages 1-2): Philipp Bosch, Milena Bond, Christian Dejaco, Cristina Ponte, Sarah Louise Mackie, Louise Falzon, Wolfgang A Schmidt, and Sofia Ramiro. Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the eular recommendations. RMD Open, 9:e003379, Aug 2023. URL: https://doi.org/10.1136/rmdopen-2023-003379, doi:10.1136/rmdopen-2023-003379. This article has 108 citations and is from a peer-reviewed journal.

  11. (comarmond2017longtermoutcomesand pages 1-4): Cloé Comarmond, Lucie Biard, Marc Lambert, Arsène Mekinian, Yasmina Ferfar, Jean-Emmanuel Kahn, Ygal Benhamou, Laurent Chiche, Fabien Koskas, Philippe Cluzel, Eric Hachulla, Emmanuel Messas, Matthieu Resche-Rigon, Patrice Cacoub, Tristan Mirault, and David Saadoun. Long-term outcomes and prognostic factors of complications in takayasu arteritis: a multicenter study of 318 patients. Circulation, 136:1114–1122, Sep 2017. URL: https://doi.org/10.1161/circulationaha.116.027094, doi:10.1161/circulationaha.116.027094. This article has 278 citations and is from a highest quality peer-reviewed journal.

  12. (fan2019clinicalcourseand pages 1-2): Luyun Fan, Huimin Zhang, Jun Cai, Lirui Yang, Bin Liu, Dongmei Wei, Jiachen Yu, Jiali Fan, Lei Song, Wenjun Ma, Xianliang Zhou, Haiying Wu, and Ying Lou. Clinical course and prognostic factors of childhood takayasu’s arteritis: over 15-year comprehensive analysis of 101 patients. Arthritis Research & Therapy, Jan 2019. URL: https://doi.org/10.1186/s13075-018-1790-x, doi:10.1186/s13075-018-1790-x. This article has 70 citations and is from a domain leading peer-reviewed journal.

  13. (nakaoka2020longtermefficacyand pages 1-2): Yoshikazu Nakaoka, Mitsuaki Isobe, Yoshiya Tanaka, Tomonori Ishii, Seido Ooka, Hiroaki Niiro, Naoto Tamura, Shogo Banno, Hajime Yoshifuji, Yasushi Sakata, Atsushi Kawakami, Tatsuya Atsumi, Shunsuke Furuta, Hitoshi Kohsaka, Katsuya Suzuki, Ryoki Hara, Yasuhiro Maejima, Hiroshi Tsukamoto, Yoshinari Takasaki, Katsuhisa Yamashita, Norihiro Okada, Shinji Yamakido, Syuji Takei, Shumpei Yokota, and Norihiro Nishimoto. Long-term efficacy and safety of tocilizumab in refractory takayasu arteritis: final results of the randomized controlled phase 3 takt study. Rheumatology (Oxford, England), 59:2427-2434, Jan 2020. URL: https://doi.org/10.1093/rheumatology/kez630, doi:10.1093/rheumatology/kez630. This article has 128 citations.

  14. (bhandari2023pathophysiologydiagnosisand pages 3-4): Sagar Bhandari, Samia Rauf R Butt, Anzal Ishfaq, Mohamed H Attaallah, Chukwuyem Ekhator, Raghu Halappa Nagaraj, Asmita Mulmi, Muhammad Kamran, Amanda Karski, Karla I Vargas, Slobodan Lazarevic, Mohammad Uzair Zaman, Gautham Lakshmipriya Vetrivendan, S M Iram Shahzed, Archana Das, Vikas Yadav, Sophia B Bellegarde, and Ashraf Ullah. Pathophysiology, diagnosis, and management of takayasu arteritis: a review of current advances. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.42667, doi:10.7759/cureus.42667. This article has 57 citations.

  15. (bhandari2023pathophysiologydiagnosisand pages 8-9): Sagar Bhandari, Samia Rauf R Butt, Anzal Ishfaq, Mohamed H Attaallah, Chukwuyem Ekhator, Raghu Halappa Nagaraj, Asmita Mulmi, Muhammad Kamran, Amanda Karski, Karla I Vargas, Slobodan Lazarevic, Mohammad Uzair Zaman, Gautham Lakshmipriya Vetrivendan, S M Iram Shahzed, Archana Das, Vikas Yadav, Sophia B Bellegarde, and Ashraf Ullah. Pathophysiology, diagnosis, and management of takayasu arteritis: a review of current advances. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.42667, doi:10.7759/cureus.42667. This article has 57 citations.

  16. (misra2023arterialwallfibrosis pages 1-2): Durga Prasanna Misra, Kritika Singh, Aman Sharma, and Vikas Agarwal. Arterial wall fibrosis in takayasu arteritis and its potential for therapeutic modulation. Frontiers in Immunology, May 2023. URL: https://doi.org/10.3389/fimmu.2023.1174249, doi:10.3389/fimmu.2023.1174249. This article has 31 citations and is from a peer-reviewed journal.

  17. (bhandari2023pathophysiologydiagnosisand pages 7-8): Sagar Bhandari, Samia Rauf R Butt, Anzal Ishfaq, Mohamed H Attaallah, Chukwuyem Ekhator, Raghu Halappa Nagaraj, Asmita Mulmi, Muhammad Kamran, Amanda Karski, Karla I Vargas, Slobodan Lazarevic, Mohammad Uzair Zaman, Gautham Lakshmipriya Vetrivendan, S M Iram Shahzed, Archana Das, Vikas Yadav, Sophia B Bellegarde, and Ashraf Ullah. Pathophysiology, diagnosis, and management of takayasu arteritis: a review of current advances. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.42667, doi:10.7759/cureus.42667. This article has 57 citations.

  18. (bhandari2023pathophysiologydiagnosisand pages 5-7): Sagar Bhandari, Samia Rauf R Butt, Anzal Ishfaq, Mohamed H Attaallah, Chukwuyem Ekhator, Raghu Halappa Nagaraj, Asmita Mulmi, Muhammad Kamran, Amanda Karski, Karla I Vargas, Slobodan Lazarevic, Mohammad Uzair Zaman, Gautham Lakshmipriya Vetrivendan, S M Iram Shahzed, Archana Das, Vikas Yadav, Sophia B Bellegarde, and Ashraf Ullah. Pathophysiology, diagnosis, and management of takayasu arteritis: a review of current advances. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.42667, doi:10.7759/cureus.42667. This article has 57 citations.

  19. (tian2024chineseguidelinefor pages 6-7): Xinping Tian and Xiaofeng Zeng. Chinese guideline for the diagnosis and treatment of takayasu’s arteritis (2023). Rheumatology and Immunology Research, 5:5-26, Mar 2024. URL: https://doi.org/10.1515/rir-2024-0002, doi:10.1515/rir-2024-0002. This article has 14 citations.

  20. (tian2024chineseguidelinefor media 1be88471): Xinping Tian and Xiaofeng Zeng. Chinese guideline for the diagnosis and treatment of takayasu’s arteritis (2023). Rheumatology and Immunology Research, 5:5-26, Mar 2024. URL: https://doi.org/10.1515/rir-2024-0002, doi:10.1515/rir-2024-0002. This article has 14 citations.

  21. (arita2024currentimmunosuppressivetreatment pages 5-5): Yoh Arita, Tomohiko Ishibashi, and Yoshikazu Nakaoka. Current immunosuppressive treatment for takayasu arteritis. Circulation Journal, 88:1605-1609, Sep 2024. URL: https://doi.org/10.1253/circj.cj-23-0780, doi:10.1253/circj.cj-23-0780. This article has 11 citations and is from a peer-reviewed journal.

  22. (NCT04300686 chunk 3): A Pilot Study in Severe Patients With Takayasu Arteritis.. Shanghai Zhongshan Hospital. 2020. ClinicalTrials.gov Identifier: NCT04300686

  23. (bhandari2023pathophysiologydiagnosisand pages 9-9): Sagar Bhandari, Samia Rauf R Butt, Anzal Ishfaq, Mohamed H Attaallah, Chukwuyem Ekhator, Raghu Halappa Nagaraj, Asmita Mulmi, Muhammad Kamran, Amanda Karski, Karla I Vargas, Slobodan Lazarevic, Mohammad Uzair Zaman, Gautham Lakshmipriya Vetrivendan, S M Iram Shahzed, Archana Das, Vikas Yadav, Sophia B Bellegarde, and Ashraf Ullah. Pathophysiology, diagnosis, and management of takayasu arteritis: a review of current advances. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.42667, doi:10.7759/cureus.42667. This article has 57 citations.

  24. (bhandari2023pathophysiologydiagnosisand pages 9-10): Sagar Bhandari, Samia Rauf R Butt, Anzal Ishfaq, Mohamed H Attaallah, Chukwuyem Ekhator, Raghu Halappa Nagaraj, Asmita Mulmi, Muhammad Kamran, Amanda Karski, Karla I Vargas, Slobodan Lazarevic, Mohammad Uzair Zaman, Gautham Lakshmipriya Vetrivendan, S M Iram Shahzed, Archana Das, Vikas Yadav, Sophia B Bellegarde, and Ashraf Ullah. Pathophysiology, diagnosis, and management of takayasu arteritis: a review of current advances. Cureus, Jul 2023. URL: https://doi.org/10.7759/cureus.42667, doi:10.7759/cureus.42667. This article has 57 citations.